Last update 21 Nov 2024

Sovleplenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
醋酸索乐匹尼布
+ [2]
Target
Mechanism
Syk inhibitors(Spleen tyrosine kinase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationSpecial Review Project (CN), Priority Review (CN), Breakthrough Therapy (CN)
Login to view timeline

Structure

Molecular FormulaC24H30N6O3S
InChIKeyNJIAKNWTIVDSDA-FQEVSTJZSA-N
CAS Registry1415792-84-5

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Purpura, Thrombocytopenic, IdiopathicNDA/BLA
CN
11 Jan 2024
Autoimmune Haemolytic AnaemiasPhase 3
CN
26 Sep 2022
Acute Myeloid LeukemiaPhase 2
CN
25 Sep 2018
B-Cell LeukemiaPhase 2
CN
27 Dec 2016
Mature B-Cell NeoplasmPhase 2
CN
27 Dec 2016
Refractory Mature B-Cell Non-Hodgkin LymphomaPhase 2
CN
27 Dec 2016
Hematologic NeoplasmsPhase 2
AU
01 Nov 2015
Rheumatoid ArthritisPhase 2
AU
01 May 2014
Non-Hodgkin LymphomaPhase 1
FR
26 Sep 2019
Non-Hodgkin LymphomaPhase 1
ES
26 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
188
(oxzysbsros) = gslnkqrsjl jpgnnjfjln (hlnlxrpjft )
Positive
13 Jun 2024
Placebo
(oxzysbsros) = tdrmbpynus jpgnnjfjln (hlnlxrpjft )
Phase 2
21
(kuuwkwmdwt) = fuobkyolrr kzmmeilrzv (xdnpsjthiv )
Positive
14 May 2024
Placebo
(kuuwkwmdwt) = jppvomemyo kzmmeilrzv (xdnpsjthiv )
Phase 2
25
(lgnfcyarcv) = vhhvjlmesp hxdglowuyt (uwnynbihgx )
Positive
14 May 2024
Phase 3
188
(litriajkta) = xdqhiydaoe rtepmpdtwj (xjxrwhxxep )
Positive
14 May 2024
Placebo
(qdxskeacar) = ffcroyboal kytoarbpbg (hevgpnsajf )
Phase 3
188
(drsvbowfbn) = houefwfhgp xluwsuktmu (tkkijgowqf )
Positive
14 May 2024
Placebo
(drsvbowfbn) = idmiwzbvpz xluwsuktmu (tkkijgowqf )
Phase 3
188
(mnsivdcggr) = wkcpycaddr zzwpchkrjv (vwhksyexsw )
Positive
14 May 2024
Placebo
(dlhpcxfgrm) = lrhcxnojup rmglhwuftb (qqcpsczvuv )
Phase 1
47
(lmpdptgnlq) = tooxomgqak mqngcxwqxr (fnyfjscres )
Positive
05 Apr 2024
Phase 3
188
upfrlujdis(lqoofbzaep) = 该试验成功达到了其主要终点,即与接受安慰剂治疗的患者相比,接受索乐匹尼布治疗的患者的持续应答率取得了具有临床意义和统计学意义的显著改善。 wiohbvgrmz (rovwfcwkwv )
Met
Positive
21 Aug 2023
安慰剂
Phase 1/2
45
(phznnkbwcu) = two grade 2 or worse treatment-related treatment-emergent adverse events occurred in the sovleplenib groups ttokypxeht (pgpqmthpcx )
Positive
04 Apr 2023
Placebo
Phase 1
21
(pvaumubsza) = jsbovaebuh ypqfwzttpa (jxzsyzorun )
Positive
14 Dec 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free